Sangui Biotech Intl Inc (SGBI) 0.0033 $SGBI
Sangui BioTech International Publishes Preliminary Figures for First Half Year
BusinessWire - Mon Feb 01, 10:00AM CST
--Increase in Granulox royalty income by 28%
SBH: 28.82 (-0.41)
Sangui BioTech International Files S-1 Registration Statement with the SEC
BusinessWire - Fri Jun 26, 5:30AM CDT
Sangui Biotech International, Inc. has filed a preliminary S-1 Registration Statement with the Securities and Exchange Commission. It is being expected that the SEC will declare the Prospectus effective within the next couple of weeks. The exact timeline depends on SEC approval procedures which cannot be anticipated by the company. The S-1 becoming effective is prerequisite for Sangui to start drawing upon the financial framework agreement with US investor Southridge as announced on May 12, 2015.
SBH: 28.82 (-0.41)
Sangui BioTech: Lower Revenues in the Third Quarter
BusinessWire - Fri May 15, 5:00AM CDT
For the nine months (as of March 31, 2015) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD116,560, an increase of 29.9% over the revenues in the first nine months of the financial year 2014 when revenues amounted to USD89,741 (previous period numbers not adjusted for exchange rate changes). In the third quarter (January through March 2015) revenues amounted to USD11,654 a decrease of 62.6% as compared with the most recent quarter(October through December 2014). According to information provided by global licensee SastoMed GmbH revenues from license fees are expected to increase significantly over the remaining quarters of the calendar year after the slump of the March quarter.
SBH: 28.82 (-0.41)
Sangui BioTech International Secures Financial Framework of $5 Million over Three Years
BusinessWire - Tue May 12, 8:00AM CDT
Sangui Biotech International, Inc. has signed an agreement securing a financial framework of USD 5 million. Under the terms of this agreement Sangui Biotech International, Inc. acquires the right to sell shares to a fund of Southridge LLC, an institutional investor, located in Connecticut and New York in the amount of up to $5 million over a period of three years. The dilution of existing shareholders is limited to a maximum of 25 million shares of common stock. The agreement is subject to Sangui filing a S-1 registration statement with the SEC.
SBH: 28.82 (-0.41)
Sangui BioTech: Revenues Slightly Improved in the First Half of the 2015 Financial Year
BusinessWire - Thu Feb 12, 5:00AM CST
For the first half (as of December 31, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD104,906 an increase of 74.0% over the revenues in the first half of the financial year 2014. In the second quarter (October through December 2014) revenues amounted to USD31,166 a decrease of 57.7% as compared with the most recent quarter(July through September 2014).
Sangui BioTech: Revenues Improved in the First Quarter of the 2015 Financial Year
BusinessWire - Thu Nov 13, 5:00AM CST
For the first quarter (as of September 30, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared with the fourth quarter of the previous financial year (as of June 30, 2014).
SBH: 28.82 (-0.41)
Sangui BioTech International officially approved as trading on OTCQB
BusinessWire - Thu Nov 06, 5:36AM CST
OTC Markets Group has officially informed Sangui Biotech International, Inc., that the application of the company for continued trading on the OTCQB venture market place for early stage and developing companies was approved of today. Subsequent to the reorganization of the OTC markets, resulting in higher transparency levels and significantly improved services for issuers and investors in particular on OTCQB, Sangui has submitted all the mandatory documents and successfully met all of the initial requirements.
SBH: 28.82 (-0.41)
Sangui BioTech Yields Revenues of over USD70,000 in Q1 2015 According to Preliminary Figures
BusinessWire - Tue Oct 07, 1:22PM CDT
According to preliminary, unaudited figures Sangui BioTech International, Inc. yielded revenues from royalties and product sales of more than USD70,000 in the course of the first quarter of its financial year 2015, ended September 30, 2014. In the fourth quarter of the 2014 financial year (ended June 30, 2014) revenues had amounted to USD43,729; in the first quarter of its financial year 2014 (ended September 30, 2014) the company reported revenues of USD26,527.
Sangui BioTech International Publishes Preliminary Figures for First Half Year
BusinessWire - Mon Feb 01, 10:00AM CST
--Increase in Granulox royalty income by 28%
SBH: 28.82 (-0.41)
Sangui BioTech International Files S-1 Registration Statement with the SEC
BusinessWire - Fri Jun 26, 5:30AM CDT
Sangui Biotech International, Inc. has filed a preliminary S-1 Registration Statement with the Securities and Exchange Commission. It is being expected that the SEC will declare the Prospectus effective within the next couple of weeks. The exact timeline depends on SEC approval procedures which cannot be anticipated by the company. The S-1 becoming effective is prerequisite for Sangui to start drawing upon the financial framework agreement with US investor Southridge as announced on May 12, 2015.
SBH: 28.82 (-0.41)
Sangui BioTech: Lower Revenues in the Third Quarter
BusinessWire - Fri May 15, 5:00AM CDT
For the nine months (as of March 31, 2015) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD116,560, an increase of 29.9% over the revenues in the first nine months of the financial year 2014 when revenues amounted to USD89,741 (previous period numbers not adjusted for exchange rate changes). In the third quarter (January through March 2015) revenues amounted to USD11,654 a decrease of 62.6% as compared with the most recent quarter(October through December 2014). According to information provided by global licensee SastoMed GmbH revenues from license fees are expected to increase significantly over the remaining quarters of the calendar year after the slump of the March quarter.
SBH: 28.82 (-0.41)
Sangui BioTech International Secures Financial Framework of $5 Million over Three Years
BusinessWire - Tue May 12, 8:00AM CDT
Sangui Biotech International, Inc. has signed an agreement securing a financial framework of USD 5 million. Under the terms of this agreement Sangui Biotech International, Inc. acquires the right to sell shares to a fund of Southridge LLC, an institutional investor, located in Connecticut and New York in the amount of up to $5 million over a period of three years. The dilution of existing shareholders is limited to a maximum of 25 million shares of common stock. The agreement is subject to Sangui filing a S-1 registration statement with the SEC.
SBH: 28.82 (-0.41)
Sangui BioTech: Revenues Slightly Improved in the First Half of the 2015 Financial Year
BusinessWire - Thu Feb 12, 5:00AM CST
For the first half (as of December 31, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD104,906 an increase of 74.0% over the revenues in the first half of the financial year 2014. In the second quarter (October through December 2014) revenues amounted to USD31,166 a decrease of 57.7% as compared with the most recent quarter(July through September 2014).
Sangui BioTech: Revenues Improved in the First Quarter of the 2015 Financial Year
BusinessWire - Thu Nov 13, 5:00AM CST
For the first quarter (as of September 30, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared with the fourth quarter of the previous financial year (as of June 30, 2014).
SBH: 28.82 (-0.41)
Sangui BioTech International officially approved as trading on OTCQB
BusinessWire - Thu Nov 06, 5:36AM CST
OTC Markets Group has officially informed Sangui Biotech International, Inc., that the application of the company for continued trading on the OTCQB venture market place for early stage and developing companies was approved of today. Subsequent to the reorganization of the OTC markets, resulting in higher transparency levels and significantly improved services for issuers and investors in particular on OTCQB, Sangui has submitted all the mandatory documents and successfully met all of the initial requirements.
SBH: 28.82 (-0.41)
Sangui BioTech Yields Revenues of over USD70,000 in Q1 2015 According to Preliminary Figures
BusinessWire - Tue Oct 07, 1:22PM CDT
According to preliminary, unaudited figures Sangui BioTech International, Inc. yielded revenues from royalties and product sales of more than USD70,000 in the course of the first quarter of its financial year 2015, ended September 30, 2014. In the fourth quarter of the 2014 financial year (ended June 30, 2014) revenues had amounted to USD43,729; in the first quarter of its financial year 2014 (ended September 30, 2014) the company reported revenues of USD26,527.
